ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 218 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q3 2021. The put-call ratio across all filers is 0.95 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $174,215 | -67.5% | 31,966 | -60.0% | 0.00% | – |
| Q2 2023 | $536,062 | +59.8% | 79,890 | +110.3% | 0.00% | – |
| Q1 2023 | $335,443 | -36.2% | 37,989 | -44.8% | 0.00% | – |
| Q4 2022 | $526,059 | +314.2% | 68,856 | +286.6% | 0.00% | – |
| Q3 2022 | $127,000 | -96.2% | 17,809 | -92.6% | 0.00% | -100.0% |
| Q1 2022 | $3,331,000 | +545.5% | 239,989 | +1207.2% | 0.00% | – |
| Q4 2021 | $516,000 | -73.7% | 18,359 | -68.2% | 0.00% | – |
| Q3 2021 | $1,962,000 | -74.7% | 57,744 | -69.5% | 0.00% | -100.0% |
| Q2 2021 | $7,742,000 | -22.1% | 189,493 | -23.2% | 0.00% | -40.0% |
| Q1 2021 | $9,933,000 | +52.2% | 246,712 | +123.5% | 0.01% | +66.7% |
| Q4 2020 | $6,526,000 | +6.9% | 110,368 | -12.1% | 0.00% | -25.0% |
| Q3 2020 | $6,106,000 | +36.5% | 125,557 | +35.8% | 0.00% | 0.0% |
| Q2 2020 | $4,472,000 | +1375.9% | 92,428 | +748.3% | 0.00% | – |
| Q1 2020 | $303,000 | – | 10,896 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |